恶性胸膜间皮瘤的免疫微环境与遗传学
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.
作者信息
Wadowski Benjamin, Bueno Raphael, De Rienzo Assunta
机构信息
Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program, Division of Thoracic and Cardiovascular Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
出版信息
Front Oncol. 2021 Jun 11;11:684025. doi: 10.3389/fonc.2021.684025. eCollection 2021.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as (PD-L1) in lung and other solid cancers. However, only a small subset of MPM patients respond to checkpoint inhibition, and this response has been varied and unpredictable across several clinical trials. Recent advances in next-generation sequencing (NGS) technology have improved our understanding of the molecular features of MPM, also with respect to its genetic signature and how this impacts the immune microenvironment. This article will review current evidence surrounding the interplay between MPM genetics, including epigenetics and transcriptomics, and the immune response.
摘要
恶性胸膜间皮瘤（MPM）是一种罕见且侵袭性强的恶性肿瘤，除手术和细胞毒性化疗外，治疗选择有限。免疫检查点抑制的成功已被发现与肺及其他实体癌中免疫相关基因如（程序性死亡受体配体1，PD-L1）的表达相关。然而，只有一小部分MPM患者对检查点抑制有反应，并且在多项临床试验中，这种反应各不相同且不可预测。新一代测序（NGS）技术的最新进展增进了我们对MPM分子特征的理解，包括其基因特征以及这如何影响免疫微环境。本文将综述围绕MPM遗传学（包括表观遗传学和转录组学）与免疫反应之间相互作用的现有证据。
相似文献
1
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的免疫微环境与遗传学
Front Oncol. 2021 Jun 11;11:684025. doi: 10.3389/fonc.2021.684025. eCollection 2021.
2
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.恶性胸膜间皮瘤免疫微环境和检查点表达：与临床病理特征及随时间推移的肿瘤内异质性的相关性。
Ann Oncol. 2018 May 1;29(5):1258-1265. doi: 10.1093/annonc/mdy086.
3
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤晚期肿瘤免疫微环境的分子和组织病理学特征。
J Thorac Oncol. 2018 Jan;13(1):124-133. doi: 10.1016/j.jtho.2017.09.1968. Epub 2017 Oct 24.
4
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.抑制 yes 相关蛋白下调人恶性胸膜间皮瘤中 PD-L1（CD274）的表达。
J Cell Mol Med. 2018 Jun;22(6):3139-3148. doi: 10.1111/jcmm.13593. Epub 2018 Mar 24.
5
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.TIM-3、LAG-3、PD-1和PD-L1作为免疫治疗检查点靶点在间皮瘤患者胸腹腔积液中大量表达。
Oncotarget. 2017 Sep 21;8(52):89722-89735. doi: 10.18632/oncotarget.21113. eCollection 2017 Oct 27.
6
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.抗 PD-1 治疗在高克隆 PD-L1 表达和 EML4-ALK 重排的上皮样间皮瘤中产生显著临床应答。
Lung Cancer. 2020 Apr;142:47-50. doi: 10.1016/j.lungcan.2020.02.006. Epub 2020 Feb 14.
7
Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.免疫检查点抑制的最新进展以及（联合）阻断TIGIT作为恶性胸膜间皮瘤新策略的潜力
Biomedicines. 2022 Mar 14;10(3):673. doi: 10.3390/biomedicines10030673.
8
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.恶性胸膜间皮瘤发病和进展的异质影响因素：生物学进展及临床意义。
Int J Mol Sci. 2018 Jan 13;19(1):238. doi: 10.3390/ijms19010238.
9
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤中免疫细胞含量的异质性。
Int J Mol Sci. 2018 Mar 30;19(4):1041. doi: 10.3390/ijms19041041.
10
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.恶性胸膜间皮瘤免疫微环境的特征揭示了患者的预后亚组。
Lung Cancer. 2020 Dec;150:53-61. doi: 10.1016/j.lungcan.2020.09.026. Epub 2020 Oct 2.
引用本文的文献
1
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma.BAG2、MAD2L1 和 MDK 是癌症驱动基因，也是恶性胸膜间皮瘤新型治疗方法的候选靶点。
Cancer Gene Ther. 2024 Nov;31(11):1708-1720. doi: 10.1038/s41417-024-00805-4. Epub 2024 Sep 12.
2
Malignant peritoneal mesotheliomas of rats induced by multiwalled carbon nanotubes and amosite asbestos: transcriptome and epigenetic profiles.多壁碳纳米管和铁石棉诱导的大鼠恶性腹膜间皮瘤：转录组和表观遗传谱。
Part Fibre Toxicol. 2024 Jan 31;21(1):3. doi: 10.1186/s12989-024-00565-x.
3
Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.人类 γδ T 细胞介导的杀伤恶性胸膜间皮瘤的三种不同机制。
Front Immunol. 2023 Mar 17;14:1058838. doi: 10.3389/fimmu.2023.1058838. eCollection 2023.
4
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms.间皮瘤恶性肿瘤与微环境：分子机制
Cancers (Basel). 2021 Nov 12;13(22):5664. doi: 10.3390/cancers13225664.
5
Pleural mesothelioma classification-update and challenges.胸膜间皮瘤分类——更新与挑战
Mod Pathol. 2022 Jan;35(Suppl 1):51-56. doi: 10.1038/s41379-021-00895-7. Epub 2021 Aug 31.
6
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.恶性胸膜间皮瘤的局部治疗和肿瘤周围基质的调控：一种转化方法。
Int J Mol Sci. 2021 Aug 20;22(16):9014. doi: 10.3390/ijms22169014.
本文引用的文献
1
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.间皮瘤中的克隆结构具有预后意义，并塑造肿瘤微环境。
Nat Commun. 2021 Mar 19;12(1):1751. doi: 10.1038/s41467-021-21798-w.
2
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
3
Intratumoral heterogeneity in cancer progression and response to immunotherapy.肿瘤进展和免疫治疗反应中的肿瘤内异质性。
Nat Med. 2021 Feb;27(2):212-224. doi: 10.1038/s41591-021-01233-9. Epub 2021 Feb 11.
4
Heterozygous germline mutations increase susceptibility to asbestos and mesothelioma.胚系杂合突变增加了石棉和间皮瘤的易感性。
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33466-33473. doi: 10.1073/pnas.2019652117. Epub 2020 Dec 14.
5
DNA Methylation of as Predictor of Overall Survival in Malignant Pleural Mesothelioma.DNA甲基化作为恶性胸膜间皮瘤总生存期的预测指标
Cancers (Basel). 2020 Nov 21;12(11):3470. doi: 10.3390/cancers12113470.
6
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.恶性胸膜间皮瘤免疫微环境的特征揭示了患者的预后亚组。
Lung Cancer. 2020 Dec;150:53-61. doi: 10.1016/j.lungcan.2020.09.026. Epub 2020 Oct 2.
7
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.达沙替尼治疗下恶性胸膜间皮瘤基因组和 T 细胞受体库异质性的演变。
Clin Cancer Res. 2020 Oct 15;26(20):5477-5486. doi: 10.1158/1078-0432.CCR-20-1767. Epub 2020 Aug 14.
8
Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.M-CSF/IL-34/CSF-1R 通路在恶性胸膜间皮瘤中的作用。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000182.
9
Chromosomal rearrangements and their neoantigenic potential in mesothelioma.间皮瘤中的染色体重排及其新抗原潜力
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S92-S99. doi: 10.21037/tlcr.2019.11.12.
10
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.胸膜间皮瘤中I型干扰素基因频繁纯合缺失赋予对溶瘤麻疹病毒的敏感性。
J Thorac Oncol. 2020 May;15(5):827-842. doi: 10.1016/j.jtho.2019.12.128. Epub 2020 Jan 13.
Zotero 插件